ESMO 2023 | CUPISCO: targeted therapies for unfavorable cancer of unknown primary

Benedikt Westphalen, MD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, discusses findings from the Phase II CUPISCO trial (NCT03498521) of precision oncology approaches in patients with newly diagnosed, unfavorable cancer of unknown primary (CUP). Patients either received the standard of care chemotherapy or a treatment strategy based on genomic profiling. The primary endpoint of progression-free survival was met, demonstrating the effectiveness of precision oncology. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.